New targeted treatments raise the bar in immunotherapy-resistant melanoma By Ogkologos - October 27, 2026 6 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Approves Acalabrutinib with Venetoclax for CLL or SLL March 4, 2026 Commemorating the Contributions of Cancer Research Greats March 12, 2021 Selpercatinib Shows Durable Efficacy in RET-Altered Thyroid Cancer August 28, 2020 Metastatic Breast Cancer: ESMO Clinical Practice Guideline May 29, 2026 Load more HOT NEWS FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma EMA Recommends Granting a Marketing Authorisation for Azacitidine The Right to be Forgotten: ESMO Calls on EU Countries to... Saying YES: Inspiring a Diverse Generation of Cancer Scientists
